TMA producing bacteria 2009 thru 2017

Back in 2009, MEBO interviewed Nigel Manning, formerly the Principal Clinical Scientists, Dept. Clinical Chemistry Sheffield Children's Hospital (now retired) in which he told us that the TMA producing bacteria in the human gut had yet to be identified (that was 9 years ago). However, since the fishing industry is so lucrative, more research had been carried out into identifying TMA producing bacteria in fish, as opposed to humans, in order to determine how fresh the fish are to determine their market value. TMA is a chemical produced by bacteria in decomposing fish.

A more recent 2017 study (Rath et al. Microbiome (2017) 5:54, DOI 10.1 186/s40168-017-0271-9), "Uncovering the trimethylamine-producing bacteria of the human gut microbiota" developed a "diagnostic framework that enabled the quantification and comprehensive characterization of the TMA-producing potential in human fecal samples"

We now look forward to Proctor & Gamble marketing Dr. Hazen's new class of compounds that inhibits TMA=production by gut bacteria.

Unlike antibiotics, which non-specifically kill gut bacteria and can lead to adverse side effects and resistance, the new class of compounds prevents microbes from making a harmful molecule linked to heart disease without killing the microbes, which are part of the gut flora and may be beneficial to overall health......Because the compounds are structurally similar to choline (called analogues), the bacterial cells are “tricked” into taking them up as nutrients...

To our knowledge, this is the most potent therapy to date for ‘drugging’ the microbiome to alter a disease process. In addition, gut bacteria are altered but not killed by this drug, and there were no observable toxic side effects,” said Dr. Hazen. “The approach developed could potentially be used to target other gut microbial pathways. We look forward to advancing this novel therapeutic strategy into humans.”
https://newsroom.clevelandclinic.org/2018/08/06/potential-new-class-of-drugs-developed-at-cleveland-clinic-may-reduce-cardiovascular-risk-by-targeting-gut-microbes/

Even though Dr. Hazen's compound was research to prevent cardiovascular disease, the fact that it inhibits gut bacteria from producing TMA from choline would be a perfect way for sufferers of TMAU to be able to eat a healthy diet meeting the Adequate Intake (AI) for Choline as recommended in 1998 by the Food and Nutrition Board of the Institute of Medicine without gut bacteria converting choline into TMA, while still keeping TMA production down to an odorless level.

---

---

María

María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

---

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :

---

A EURORDIS and NORD Member Organization